Browse studies

Find your next paid study

67 recruiting studies matching your filters

The Myelin Disorders Biorepository Project and Global Leukodystrophy Initiative Clinical Trials Network

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to s…

LeukodystrophyWhite Matter DiseaseLeukoencephalopathies+63 more

Estimated

~$10 – $750

Children's Hospital of PhiladelphiaNCT03047369

Phase 1

A Phase I Trial of Revumenib in Combination With 7+3 (7 Days of Cytarabine and 3 Days of Daunorubicin) + Midostaurin Induction Chemotherapy for the Frontline Treatment of NPM1 and FLT3 Mutated AML

This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy …

Acute Myeloid LeukemiaAML, AdultAML With Gene Mutations+2 more

Estimated

~$10 – $7,500

Richard Stone, MDNCT06313437

Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer

A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targ…

Non-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene Mutation+3 more

Estimated

~$10 – $750

University of Colorado, DenverNCT03042221

Phase 2

A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People With Cystic Fibrosis

ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy …

Cystic FibrosisCFTR Gene Mutation

Estimated

~$10 – $8,750

Arcturus Therapeutics, Inc.NCT06747858

INTERogating Cancer for Etiology, Prevention and Therapy Navigation (INTERCEPTioN)

This study is being done to identify markers and causes of cancer by analyzing patient's DNA (i.e., genetic material), RNA, plasma, tissues, or other samples t…

CancerCancer Gene MutationPAN Gene Mutation+2 more

Estimated

~$10 – $750

Mayo ClinicNCT06008392

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with k…

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionUnaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo+1 more

Estimated

~$10 – $750

Vanderbilt University Medical CenterNCT05584722

Phase 1

A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of…

OncologyMEK MutationRAF Gene Mutation+6 more

Estimated

~$10 – $8,750

Nested Therapeutics, IncNCT06326411